1 / 21

18.7.2004 Internationales Forum zur Anwendung von Taheebo Osaka / Japan

18.7.2004 Internationales Forum zur Anwendung von Taheebo Osaka / Japan. ZENTRUM NOSOMI ALLGEMEINMEDIZIN, ONKOLOGIE, NATURHEILVERFAHREN ÄRZTLICHE LEITUNG: Dr.Dr. HELMUT BACOWSKY. 1200 Wien, Sachsenplatz 9/30 Tel.: +43 1 330 85 62, Fax: +43 664 507 81 82 E-Mail: nosomi@nosomi.at www.nosomi.at.

gwendolyn-fuller
Download Presentation

18.7.2004 Internationales Forum zur Anwendung von Taheebo Osaka / Japan

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 18.7.2004Internationales Forum zur Anwendung von TaheeboOsaka / Japan

  2. ZENTRUM NOSOMIALLGEMEINMEDIZIN, ONKOLOGIE, NATURHEILVERFAHRENÄRZTLICHE LEITUNG: Dr.Dr. HELMUT BACOWSKY 1200 Wien, Sachsenplatz 9/30 Tel.: +43 1 330 85 62, Fax: +43 664 507 81 82 E-Mail: nosomi@nosomi.atwww.nosomi.at

  3. Short Report on Intratumoral Application of Taheebo Extract in Combination with ECT (Electro-Chemical-Therapy) in 18 Patients suffering from Cancer of the Prostate Bacowsky H. www.nosomi.at

  4. Cancer of the prostateIncidence:Austria 2000:4.925 patients EU:42,61 cases / 100.000 inhabitants Mortality:14,65 /100.000 • (Statistic Austria, Gesundheitsbuch 2002).

  5. Are there side effects when Taheebo-extract is injected directly into the prostate? Are there risks for incontinence ? impotence ? reoccurrence ? metastasis? Is prolongation of remission possible? Is there a positiveinfluence on quality of life? Purpose of investigation: www.nosomi.at

  6. This investigation is based on individual cases, no exclusions have been performed • Each patient was informed thoroughly and in detail about risks concerning side effects, prognosis, relapse and possibility of metastasis compared with established therapies like operation, radiation, brachytherapy, hormonblockade.

  7. 18 patients, mean age 70,2years (max.96 min. 51years ) with prostate cancer, verified by biopsy Gleason score, mean 5,1 ranging from 3 to 7 Bone metastasis present before treatment (3) Male hormone blockage before ECT+Taheebo application (3) being continued after treatment (3) male hormone blockage after ECT+Taheebo, new application (3) Chemotherapy, operation and radiation before ECT+Taheebo application (0). Methode:

  8. Status before treatment

  9. ECT (Electro-Chemical-Therapy) • ECT: In the case of initial or progressed cancer of the prostate ECT provides a possible effective minimal invasive  treatment using electricity provided by a DC-device. After local anaesthesia 2 electrodes made out of platin are inserted via the perineum into the prostate. Then a currency of 7-7.5 Volt is administered for about 40-50 minutes depending on the size of the prostate. At the end of treatment the electrodes are removed. Sideeffects like mild haematuria or impairment of urination can be possible, but as we have seen in more than 57 patients so far, these side effects happened only in 2 cases.

  10. Taheebo-extract • was prepared by boiling down30gTabebuia av. powder (provided by Taheebo Japan Co.) with 500 ml water in a glass jar for 40 minutes. Decoct and sediment was transferred into 10 ml vials, which were then sterilised at 120ο C for 2 hours. Probes were tested on bacterial contamination (ARGE Graz) and analysed for content of Furan-Naphtochinon (Laboratories of Kyoto Prefectural University of Medicine). Each 10 ml vial contained25mgFuran-Naphtochinon • Immediately after ECT platin electrodes were removed and via syringe 5-10ml Tabebuia-extract was injected directly into the prostate • PSA-levels were determined before treatment and every 6-8 months after therapy, sonographic and physical examination were done and Quality of life assessed by using a standard questionnaire (TOC)

  11. Results: side effects

  12. Results/結果 30 months Observation/経過観察期間３０ヶ月 • 3 patients out of 18 died, two patients due to additionalchemotherapy performed in another clinic, 25 months and 30 months after ECT/Taheebo, one died of old age. • １８　症例中３人死亡。そのうち２人は、他の病院で化学療法を受けたことが原因。通電治療とタヒボ注入後、２５ヶ月と３０ヶ月生存。もう１人は、老衰による。 • 6 patientsunderwent therapy withmale hormone blockingagent • ６症例はホルモン遮断剤の治療を受けた。 • 3already some timebefore treatment,because2 out of 3hadbone metastasis • ３症例は通電治療とタヒボ注入前にホルモン遮断剤を受けた。そのうちの２人は既に骨転移が認められていた。

  13. Results/結果 • 3 received hormone blockade immediately after ECT/Taheebo. • ３症例は、通電治療とタヒボ注入直後、予防としてホルモン療法を行った。 • 15 patients are still alive, no relapse or bone metastasis in those patients who had none before treatment, no marked progression in those 2 patients with bone metastasis who were treated by hormone blockade and biphosphonate infusion at regular interval. One patient with bone metastasis before ECT/Taheebo therapy is stable with only slow progress observed, neither treated with a hormone blocking agent nor receiving biphosphonate infusions. • １５症例　全て生存中、治療前に再発、骨転移のなかった患者は、その状態を保っている。骨転移のあった２人の患者は治療後、顕著な進行を認めていない。 • 12 patients without new metastasis during 30 months of observation. • １２症例では、新たな骨転移は認められない。

  14. Results:

  15. Results: • Individual PSA-levels differ in a wider range, elevation can be observed 4-6 months after treatment, due to manipulation of the prostate, dropping then or also rising again after 6-8 months, though no visible metastasis are detectable in bones by szintigraphy. • In those cases an examination by PET and molecular genetic evaluation of minimal residual cancer cells in peripheral blood will be done in a next step.

  16. Results: Individual PSA level performance

  17. Results:

  18. Nearly pain free treatment No severe side effects No allergic reactions No impairment of libido and sexual function No incontinence No hospitalisation Patient is mobile immediately after treatment able to work within the next day low cost compared to operation, radiation ほとんど痛みを伴わない治療 ほとんど副作用を伴わない アレルギー反応なし 性欲、性機能を損なわない 失禁がない 外来治療のみ 治療後、即、動ける 翌日から仕事　復帰可能 治療費が安価 Summery/結論ECT/Taheebo を手術、化学療法、放射線治療と比較 • ECT/Taheebo 利点

  19. Not yet approved method Too small number of patients with only 30 months of observation Further investigations necessary 公に認可された治療法ではない 症例が少なく、経過観察の期間も短い、３０ヶ月のみ 今後も研究が必要 Summery/結論ECT/Taheebo を手術、化学療法、放射線治療と比較 • ECT/Taheebo 考慮点

  20. Conclusion: • Prospective follow ups of patients of this pilot study are planned • Data will be compared with patient´s treated with other methods • Future investigations are planned to see, wether a combination of one or multiple injections in a certain interval combined with oral administered Taheebo can be helpful to suppress cancer growth in the prostate. • Further Investigations will be directed using Taheebo extractin cell cultures ondifferent wild type human cancer cellstrains to • show a possible direct cytostatic effect • To elucidatethe potential of Taheebo extract as anapoptosis inducing agent on a moleculargenetic level • enhancing BAX protein reducing Bcl2 gene expression • reducing MDR-RNA levels in vivo, minimising drug resistance, implementing the possibility of lower dosage of toxic chemo therapeutics.

  21. ZENTRUM NOSOMIALLGEMEINMEDIZIN, ONKOLOGIE, NATURHEILVERFAHRENÄRZTLICHE LEITUNG: Dr.Dr. HELMUT BACOWSKY 1200 Wien, Sachsenplatz 9/30 Tel.: +43 1 330 85 62, Fax: +43 664 507 81 82 E-Mail: nosomi@nosomi.at, www.nosomi.at

More Related